Seroprevalence of Antibodies to Varicella-zoster Virus in Madrid (Spain) in the Absence of Vaccination

Abstract

Objective: to ascertain the seroprevalence of antibodies to varicella-zoster virus in the Madrid population prior to the introduction of vaccination. Study design: Cross-sectional antibody seroprevalence study. Methods: Population: persons aged 2 to 40 years in Madrid. Field work: September 1999 to April 2000. Data were collected on demographic and socioeconomic variables and on a number of exposures. IgG antibodies were determined using Enzyme Linked ImmunoSorbent Assay (ELISA), and antibody prevalence broken down by age group. Logistic regression was used to analyse the association between the presence of antibodies and the respective study variables. The results were compared against those of an earlier seroprevalence survey in Madrid (1993). Results: A total of 2,131 subjects were included, with a non-response rate of 20.4%. Antibody prevalence was estimated at 90.2%; the 90% mark was reached at 11 years of age and almost 100% of adults presented with antibodies. In the case of children, school attendance associated with the presence of antibodies. No significant differences were observed vis-à-vis the results of the earlier survey. Conclusions: The seroprevalence profile coincides with those of other Spanish regions and European countries, and remains stable over time. Antibody presence rises sharply in children from aged 2 years to adolescence. Further seroprevalence studies are called for to study the disease trend and assess preventive measures.

Prevalence of specific antibody to hepatitis E virus in the general population of the community of Madrid, Spain

“…Sampling was done as described for the third Survey [Pérez-Farinós et al, 2008], but including people aged 41-60 years. Serum samples were collected from January to May 2008.…”

Evaluation of Mandatory Case-based Reporting System for Varicella in the Prevaccine Era

“…Seroprevalence studies demonstrated varicella specific antibodies in more than 90% of ten-year-olds (19). During the prevaccine period, the majority of varicella cases were in children and primary school students seen by paediatricians and school physicians.…”

Long Term Persistence of IgE Anti-Varicella Zoster Virus in Pediatric and Adult Serum Post Chicken Pox Infection and after Vaccination with Varicella Virus Vaccine

“…Patients are given two doses of the live attenuated varicella vaccine (Varivax©, Merck and Company, Inc, West Point, PA) according to the recommended schedule of the American Academy of Pediatrics (23). Studies have reported the presence of IgG antibodies to VZV in healthy (non-vaccinated) children (24,25) and antibodies against VZV and rubella virus (26), in the absence of vaccination. VZV seroprevalence was highest in these children at 48 and 60 months old (25).…”